Poland· PL-100461329
Asigefort
A medicinal product containing sitagliptinum + metformini hydrochloridum, registered in Poland by Tad Pharma GmbH.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Sitagliptinum + Metformini hydrochloridum
- Manufacturer
- Tad Pharma GmbH
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin03838989753412
- gtin03838989753405
- gtin03838989752620
- gtin03838989752613
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sitagliptinum + metformini hydrochloridum in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaASIGEFORTTAD Pharma GmbH, Cuxhaven
- SpainDISIMET 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGLaboratorios Alter S.A.
- SwitzerlandJanumet
- NetherlandsEfficib 50 mg/1000 mg, filmomhulde tablettenMerck Sharp & Dohme B.V.
- United StatesJANUMETA-S Medication Solutions
- SwedenEfficib 50 mg/1000 mg Filmdragerad tablettMerck Sharp & Dohme BV
- FinlandBrandasitGenepharm S.A.
- ItalyADIABINPHARMEXTRACTA S.P.A.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Jamesi, Jansitin Duo
- Belgium · Sitagliptin/Metformin Grindeks, Sitagliptin/Metformin Sandoz
- Bulgaria · Jansitin Duo, Metlinka 50 Mg/1000 Mg
- Cyprus · Diabremet, Jivolar
- Czechia · Ansifora Duo, Asigefort
- Germany · Metformax Combi, Metsunix
- Denmark · Glerova, Sitagliptin/Metformin "sandoz"
- Estonia · Asigefort, Diabremet
- Spain · Disimet, Estequen
- Finland · Brandasit, Sitagliptin/Metformin Glenmark
- France · Sitagliptine/Chlorhydrate De Metformine Micro Labs, Sitagliptine/Chlorhydrate De Metformine Olpha
- United Kingdom (Northern Ireland) · Sitagliptin / Metformin Hydrochloride Macleods, Sitagliptin / Metformin Hydrochloride Macleods Pharma Uk
- Greece · Brandasit, Co-Fineria
- Croatia · Condias Combi, Eprocliv
- Hungary · Ansifora Duo, Asigefort
- Ireland · Sitagliptin And Metformin Hydrochloride Ascend, Sitagliptin/Metformin Clonmel
- Iceland · Aps, Efficib
- Italy · Adiabin, Diesmit
- Liechtenstein · Efficib, Janumet
- Lithuania · Asigefort, Eprocliv
- Latvia · Asigefort, Eprocliv
- Malta · Combodiab Galenicum Health, Diabremet
- Netherlands · Eprocliv, Fordiab
- Norway · Efficib, Janumet
- Portugal · Jivolar, Metformina + Sitagliptina Alter
- Romania · Eprocliv, Jamesi
- Sweden · Jivolar, Mifomet
- Slovenia · Eprocliv, Jivolar
- Slovakia · Ansifora Duo, Asigefort
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6b7cef9a-1611-4396-832d-b707131aaba4 GET /v1/drugs/6b7cef9a-1611-4396-832d-b707131aaba4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 850 mg",
"packaging": "03838989753412 ¦ Rp ¦ 149826\n56 tabl.\n03838989753405 ¦ Rp ¦ 149827\n28 tabl.\n03838989752620 ¦ Rp ¦ 149828\n56 tabl.\n03838989752613 ¦ Rp ¦ 149829\n28 tabl.",
"substance": "Sitagliptinum 50 mg + Metformini hydrochloridum 850 mg",
"common_name": "Sitagliptinum + Metformini hydrochloridum",
"pl_product_id": "100461329",
"pozwolenie_nr": "27790",
"auth_procedure": "DCP",
"authorisation_validity": "2028-04-14"
}See everything about sitagliptinum + metformini hydrochloridum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.